Listar por tema "Cytochrome P-450 CYP2D6/metabolism"

Mostrando ítems 1-1 de 1

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

St-Jean, Pamela-L.; Xue, Zhengyu; Carter, Nick; Koh, Gavin-C. K. W.; Duparc, Stephan; Taylor, Maxine; Beaumont, Claire; Llanos Cuentas, Elmer Alejandro; Rueangweerayut, Ronnatrai; Krudsood, Srivicha; Green, Justin-A.; Rubio, Justin-P. (BioMed Central, 2016)

Background: Tafenoquine (TQ) and primaquine (PQ) are 8-aminoquinolines (8-AQ) with anti-hypnozoite activity against vivax malaria. PQ is the only FDA-approved medicine for preventing relapsing Plasmodium vivax infection ...